menu
    • menu
    [{"orgOrder":0,"company":"AiCuris","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AiCuris \/ Quintiles Inc","highestDevelopmentStatusID":"15","companyTruncated":"AiCuris \/ Quintiles Inc"},{"orgOrder":0,"company":"AiCuris","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"AiCuris","amount2":0.22,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.22,"dosageForm":"Tablet, Film Coated","sponsorNew":"AiCuris \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AiCuris \/ Royalty Pharma"},{"orgOrder":0,"company":"AiCuris","sponsor":"FHI 360","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pritelivir","moa":"Helicase\/primase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AiCuris \/ FHI 360","highestDevelopmentStatusID":"8","companyTruncated":"AiCuris \/ FHI 360"},{"orgOrder":0,"company":"AiCuris","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pritelivir","moa":"Helicase\/primase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AiCuris \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"AiCuris \/ Medpace, Inc"},{"orgOrder":0,"company":"AiCuris","sponsor":"Novella Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pritelivir","moa":"Helicase\/primase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"AiCuris \/ Novella Clinical","highestDevelopmentStatusID":"8","companyTruncated":"AiCuris \/ Novella Clinical"},{"orgOrder":0,"company":"AiCuris","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pritelivir","moa":"Helicase\/primase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AiCuris \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"AiCuris \/ Medpace, Inc"},{"orgOrder":0,"company":"AiCuris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pritelivir","moa":"Helicase\/primase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AiCuris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AiCuris \/ Undisclosed"},{"orgOrder":0,"company":"AiCuris","sponsor":"Impatients N.V. trading as myTomorrows","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pritelivir","moa":"Helicase\/primase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AiCuris \/ Impatients N.V. trading as myTomorrows","highestDevelopmentStatusID":"8","companyTruncated":"AiCuris \/ Impatients N.V. trading as myTomorrows"},{"orgOrder":0,"company":"AiCuris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pritelivir","moa":"Helicase\/primase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AiCuris \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AiCuris \/ Undisclosed"},{"orgOrder":0,"company":"AiCuris","sponsor":"myTomorrows","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Pritelivir","moa":"Helicase\/primase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AiCuris \/ AiCuris","highestDevelopmentStatusID":"8","companyTruncated":"AiCuris \/ AiCuris"},{"orgOrder":0,"company":"AiCuris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pritelivir","moa":"Helicase\/primase","graph1":"Undisclosed","graph2":"Phase I","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AiCuris \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AiCuris \/ Undisclosed"},{"orgOrder":0,"company":"AiCuris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AIC468","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AiCuris \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AiCuris \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by AiCuris

    Menu

    AiCuris

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AIC468

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AiCuris Launches Phase 1 Trial of AIC468 for BK Virus in Transplant Patients

                            Details : AIC468 is an antiviral agent which aims to treat BK virus (BKV) infections in kidney transplant (KT) recipients, by inhibiting BKV replication.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 31, 2024

                            Lead Product(s) : AIC468

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Impatients N.V. trading as myTomorrows

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects with Treatment...

                            Details : Pritelivir is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Herpes Simplex.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 06, 2023

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Impatients N.V. trading as myTomorrows

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Thorough QT/QTc of Pritelivir in Healthy Subjects

                            Details : Pritelivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 04, 2023

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir

                            Details : Pritelivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Herpesviridae Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 24, 2022

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Letermovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Royalty Pharma

                            Deal Size : $220.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Royalty Pharma Acquires Partial Royalty Interest On Prevymis™ (Letermovir) From Aicuris Anti-Infective Cures...

                            Details : Prevymis™ (letermovir) was approved by the US FDA in 2017 and by the EMA and Japan’s PMDA in 2018 for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant who are at high ri...

                            Product Name : Prevymis

                            Product Type : Miscellaneous

                            Upfront Cash : $220.0 million

                            June 09, 2020

                            Lead Product(s) : Letermovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Royalty Pharma

                            Deal Size : $220.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AiCuris Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir to Treat HSV Infections in Immunoc...

                            Details : Receiving Breakthrough Therapy Designation will facilitate AiCuris goal of bringing pritelivir to patients as quickly as possible . Company is now preparing to add a pivotal Phase 3 trial part to the ongoing Phase 2 study in immunocompromised patients.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 05, 2020

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : myTomorrows

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AiCuris collaborates with myTomorrows

                            Details : The companies are collaborating to develop an Early Access Program for pritelivir, for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 12, 2020

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : myTomorrows

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Her...

                            Details : Pritelivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Herpesviridae Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 08, 2017

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Novella Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes

                            Details : Pritelivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Herpes Labialis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 18, 2016

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Novella Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            AiCuris

                            Germany arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes

                            Details : AIC316 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Herpes Genitalis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 07, 2012

                            Lead Product(s) : Pritelivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth